Prevention & care

Endometrial cancer: the uterine lining, abnormal bleeding, biopsy, molecular findings, and care

8 sources · Latest source check 2026-10-08 UTC

On this page

Endometrial cancer begins in the lining of the uterus, called the endometrium. The uterus also has a muscular wall and a cervix. Cancer beginning in the lining, uterine sarcoma and cervical cancer need different explanations, even though these structures are nearby.[1]

Nearby structures, different disease settings

Nearby structures, different disease settings
Structure	What it means
Endometrium	Inner uterine lining; the origin of endometrial cancer.[1]
Myometrium	Muscular uterine wall; invasion into it affects assessment.[2]
Cervix	Lower end of the uterus; cervical cancer has its own pathway.[1]

A thickened lining is a finding, not a complete diagnosis

NCI describes endometrial hyperplasia as increased lining growth that can, in some circumstances, precede cancer. Thickness on ultrasound cannot by itself establish the tissue category or diagnose cancer. Pathological assessment provides different information.[2]

Bleeding after menopause deserves prompt assessment

NHS lists bleeding or spotting after menopause, unusual heavy periods, bleeding between periods and changed discharge as possible symptoms. Many other conditions can cause them, but assessment should not be delayed. A reassuring earlier cervical-screening result does not answer why new bleeding has occurred.[4]

Hysteroscopy, ultrasound and biopsy are different tests

NHS describes transvaginal ultrasound, viewing the uterine cavity with a small camera, and sampling the lining. Hysteroscopy visualizes the cavity; biopsy supplies tissue for microscopic examination. Which procedures are used depends on the findings. Discuss comfort, pain management, consent and when results or further assessment are expected.[5]

A Pap test does not screen the uterine lining

NCI explains that Pap testing samples the cervix and vagina and is not used to screen for endometrial cancer. It can occasionally reveal findings that lead to further investigation. A normal result cannot rule out a cancer in the lining, and symptom assessment serves a different purpose.[3]

Cell type, grade and stage should retain their separate labels

The professional NCI summary distinguishes endometrioid, serous, clear-cell and other histologies. Grade concerns cellular appearance; stage concerns disease extent and other classification features. Neither a grade nor a type alone supplies a complete prognosis.[2]

Examples of molecular classification labels

Examples of molecular classification labels
Label	Meaning
POLEmut	A pathogenic POLE change.[2]
MMRd	Mismatch-repair deficiency.[2]
p53abn	An abnormal TP53/p53 classification.[2]
NSMP	No specific molecular profile in this classification.[2]

A modern stage label needs its classification context

NCI describes FIGO systems that incorporate tissue and molecular findings differently. Ask which staging edition is being used and how the findings affect care; labels alone cannot select treatment.[2]

Hormonal and inherited risks do not establish a diagnosis

NHS identifies hormonal exposure, metabolic factors, some medicines and Lynch syndrome among relevant risks. Risk does not mean inevitability. A medicine’s risks must be considered with its benefits; this page does not recommend stopping tamoxifen or changing hormone therapy. New bleeding should be discussed with the treating team.[6]

Tumor classification and inherited-risk assessment serve different purposes

NHS explains that genetic assessment can sometimes identify Lynch syndrome and lead to specialist advice for the person and family. A tumor report should prompt clear explanation of which findings describe the cancer and which need separate inherited-risk investigation. This page does not interpret a personal genetic result.[5]

Hysterectomy and ovary removal are different operations

NCI distinguishes removing the uterus and cervix from removing both ovaries and tubes. A proposed operation should specify which structures are involved and why. Treatment after surgery may aim to lower recurrence risk; that aim differs from treating visible remaining cancer.[7]

External and internal radiation are different delivery methods

NCI describes radiation delivered from a machine or a source positioned inside or near the cancer. Its purpose can include disease treatment or symptom relief. The older patient page explains these concepts but should not be treated as a current ranking of all systemic medicines.[7]

Benefits, harms, fertility and follow-up should be part of the explanation

NHS describes surgery, radiation, chemotherapy and selected hormone or immune treatments. Choices depend on disease and overall health. Care discussions should explain expected benefit, adverse effects, fertility consequences and follow-up. A label such as “immunotherapy” cannot establish suitability or response for an individual cancer.[8]

Evidence & uncertainty

Abnormal bleeding needs assessment; it does not automatically mean cancer. NCI reports no standard routine screening test for endometrial cancer. Uncertainty about screening benefit concerns symptom-free testing and should not be used to dismiss bleeding after menopause or other new changes.[3][4]

Selected-source overview · Independent review pending

Published questions

Is endometrial cancer the same as cervical cancer?

Selected-source overview · Independent review pending. Read the evidence context.

They begin in different tissues and have different care pathways.[1]

Evidence behind this answer

What Is Endometrial Cancer?
agency condition or prevention explanation · 2020
Selected relevant original official page passages inspected · Lining, cervix and distinction from uterine sarcoma